Mobile

An Open-label, Multi-Center, Phase I/II Trial Investigating the Pharmacokinetic profile of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in non-curable patients with SCCHN

Update Il y a 4 ans
Reference: EUCTR2009-013317-10

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To determine key pharmacokinetic parameters for zalutumumab as monotherapy in patients with SCCHN.

Inclusion criteria

  • Non-Curable Squamous cell carcinoma of the head and neck (SCCHN)

Links